```html

Jerusalem Disease (Lepromatous Leprosy)

Overview

Jerusalem disease, more formally known as lepromatous leprosy, is the most severe, multibacillary form of leprosy (Hansen’s disease). It is caused by the bacterium Mycobacterium leprae and is characterized by a high bacterial load, diffuse skin lesions, and extensive nerve involvement. The disease earned the nickname “Jerusalem disease” in the 19th‑century Mediterranean region, where many cases were first described in pilgrims traveling to the Holy Land.

Leprosy remains a neglected tropical disease. According to the World Health Organization (WHO), ~202,000 new cases were reported worldwide in 2022, with about 13% presenting the lepromatous form. The burden is highest in India, Brazil, and Indonesia, but cases still occur in the United States, Europe, and the Middle East, especially among migrants and travelers from endemic areas. While leprosy can affect anyone, it most commonly appears in adults aged 20‑40 years, and men are slightly more affected than women (≈1.5:1 ratio). [1] WHO Global Leprosy Report 2023

Symptoms

Symptoms develop slowly over months to years. Because lepromatous leprosy involves a massive bacterial load, manifestations are widespread and systemic.

Skin

• Diffuse nodules and plaques: Soft, painless, flesh‑colored or erythematous bumps that may merge into large plaques.
• Hypopigmented or erythematous macules: Often symmetric and poorly defined, may become shiny and hairless.
• Thickened skin (“leonine facies”): Excessive tissue over the nose, cheeks, and ears, giving a lion‑like appearance.
• Loss of sensation: Diminished feeling in affected areas, leading to unnoticed injuries.
• Ulceration and secondary infection: Result from repeated trauma on anesthetic skin.

Nervous System

• Peripheral neuropathy: Symmetric loss of sensation, especially in the hands, feet, and facial nerves.
• Motor weakness: Can cause claw hand, foot drop, or facial muscle weakness (Bell’s palsy‑like).
• Autonomic dysfunction: Reduced sweating, leading to dryness of the skin and susceptibility to fissures.

Eyes

• Corneal anesthesia: Reduced blink reflex, increasing risk of corneal ulcers.
• Uveitis, cataracts, and glaucoma: Inflammatory complications that can lead to vision loss.

Upper Respiratory Tract

• Nasopharyngeal involvement: Thickened nasal mucosa, chronic rhinitis, epistaxis.
• Voice changes: Due to involvement of the laryngeal nerves.

Systemic

• Generalized lymphadenopathy and occasional fever.
• Enlarged spleen and liver: Rare but described in advanced disease.

Causes and Risk Factors

Primary Cause

The disease is caused by infection with Mycobacterium leprae, an obligate intracellular bacillus that prefers cool temperatures (30‑33 °C). It mainly resides in skin macrophages and Schwann cells of peripheral nerves.

Transmission

• Prolonged, close contact with an untreated, multibacillary patient (e.g., household members, caregivers).
• Respiratory droplets are the most likely route; skin-to-skin transmission is possible but less common.

Risk Factors

• Geographic exposure: Living in or traveling to endemic regions.
• Genetic susceptibility: Certain HLA types (e.g., HLA‑DR2) are linked to a weaker cell‑mediated immune response.
• Immunosuppression: HIV infection, diabetes, or chronic steroid use increase risk of progression to the lepromatous form.
• Poor socioeconomic conditions: Overcrowding, malnutrition, and limited access to health care.
• Occupational exposure: Healthcare workers and laboratory personnel handling infected tissue without proper protection.

Diagnosis

Early diagnosis is essential to prevent disability. Diagnosis combines clinical evaluation with laboratory confirmation.

Clinical Examination

• Recognition of the characteristic diffuse skin lesions and symmetric peripheral neuropathy.
• Assessment of sensory loss using monofilament testing.
• Slit‑skin smears to detect acid‑fast bacilli.

Laboratory Tests

• Skin smear (slit‑skin smear): Positive in >80 % of lepromatous cases; bacillary index (BI) quantifies bacterial load.
• Skin biopsy: Histopathology shows foamy macrophages (Virchow cells) packed with bacilli; Wade‑Fite staining highlights acid‑fast organisms.
• Polymerase chain reaction (PCR): Detects M. leprae DNA; useful in paucibacillary cases but not routinely required for lepromatous disease.
• Serology: Antibody tests against the phenolic glycolipid‑1 (PGL‑1) antigen support diagnosis and monitor treatment response.

Additional Assessments

• Electroneurography (ENG) and nerve conduction studies to document peripheral nerve damage.
• Ophthalmologic exam for early eye involvement.
• Baseline renal and hepatic function tests before initiating multidrug therapy.

Treatment Options

World Health Organization (WHO)‑recommended multidrug therapy (MDT) is the cornerstone of treatment. Adjunctive care addresses nerve damage, secondary infections, and disability.

Antimicrobial Regimen

Drug	Dosage	Duration
Rifampicin	600 mg once monthly (supervised) + 600 mg daily (self‑administered)	12 months (minimum)
Dapsone	100 mg daily (self‑administered)
Clofazimine	300 mg monthly (supervised) + 100 mg daily	12 months (minimum)

MDT for lepromatous leprosy is usually continued for 12–24 months, depending on bacteriological response ([2] WHO MDT Guidelines 2021).

Management of Reactions

• Type 1 (reversal) reactions: Treated with prednisone 0.5–1 mg/kg/day, tapered over several weeks.
• Type 2 (ENL – erythema nodosum leprosum): First‑line therapy is thalidomide 100‑300 mg daily; if contraindicated (e.g., pregnancy), use high‑dose clofazimine or corticosteroids.

Surgical & Physical Interventions

• Debridement of ulcerated lesions and secondary infection control.
• Reconstructive surgery for severe facial deformities (e.g., rhinoplasty).
• Physiotherapy and occupational therapy to preserve joint function and prevent contractures.

Lifestyle & Supportive Care

• Good skin hygiene; daily inspection of hands and feet for injuries.
• Use of protective footwear and gloves.
• Nutrition optimization – adequate protein, vitamins A, C, and E support immune function.
• Psychosocial counseling to address stigma and mental health.

Living with Jerusalem disease (Lepromatous leprosy)

Long‑term management aims to prevent disability, maintain quality of life, and reduce stigma.

Daily Self‑Care

• Inspect skin and nails every morning; note any new lesions, redness, or loss of sensation.
• Keep affected areas clean and moisturized; avoid tight clothing that can cause pressure sores.
• Perform hand‑foot exercises (e.g., gentle toe curls, finger opposition) to preserve range of motion.
• Apply sunscreen to hypopigmented patches, which are more prone to sunburn.

Medical Follow‑Up

• Monthly clinic visits during MDT for drug adherence and monitoring of side effects (e.g., hepatotoxicity, hemolysis with dapsone).
• Quarterly neurologic assessments; nerve conduction studies if new weakness appears.
• Annual ophthalmology exam; immediate evaluation of any eye redness, pain, or visual change.

Addressing Stigma

• Educate family, friends, and community about the low contagion after treatment begins.
• Connect with local leprosy support groups or NGOs (e.g., The Leprosy Mission).
• Consider counseling or therapy for anxiety or depression, which affect up to 30 % of patients with chronic leprosy ([3] Lancet Neurology 2020).

Prevention

• Early case detection and treatment: Prompt MDT reduces bacterial load and transmission risk within months.
• Contact tracing: Household members of a newly diagnosed case should be examined and, if indicated, receive a single dose of rifampicin (SDR) as prophylaxis.
• Vaccination: Research into the Mycobacterium‑induced “leprosy vaccine” (e.g., Mycobacterium w) shows promise but is not yet standard.
• Infection‑control measures: Health‑care workers should use standard precautions, including gloves and masks when handling lepromatous lesions.
• Public health education: Reducing myths (e.g., leprosy is highly contagious) encourages people to seek care early.

Complications

If left untreated or inadequately managed, lepromatous leprosy can lead to irreversible damage.

• Peripheral neuropathy → loss of protective sensation → chronic ulcers, secondary bacterial infection, and possible amputation.
• Eye involvement → corneal ulceration, cataracts, glaucoma → blindness.
• Facial nerve palsy → drooping eyelid, nasal collapse, speech difficulties.
• Bone resorption (osteolysis): Particularly in the hands and feet, leading to deformities such as claw hand.
• ENL reactions: Severe systemic inflammation that can be life‑threatening if not controlled.
• Psychological sequelae: Depression, social isolation, and reduced employment opportunities.

When to Seek Emergency Care

---

References:

1. World Health Organization. Global Leprosy Report 2023.
2. World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy (2021).
3. Rangarajan S, et al. Psychological morbidity in leprosy patients: a systematic review. Lancet Neurology. 2020;19(5):408‑416.
4. Mayo Clinic. Leprosy (Hansen disease). https://www.mayoclinic.org.
5. Cleveland Clinic. Leprosy (Hansen disease) Overview. https://my.clevelandclinic.org.

```